Angiogenesis in hematologic malignancies

被引：56

作者：

Moehler, TM ^{[1
]}

Neben, K ^{[1
]}

Ho, AD ^{[1
]}

Goldschmidt, H ^{[1
]}

机构：

[1] Heidelberg Univ, Dept Internal Med 5, D-69115 Heidelberg, Germany

来源：

ANNALS OF HEMATOLOGY | 2001年 / 80卷 / 12期

关键词：

angiogenesis; vasculogenesis; leukemia; lymphoma; multiple myeloma;

D O I：

10.1007/s00277-001-0398-3

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Angiogenesis defined as the blood vessel generation from preexisting blood vessels was found to play an important role in the progression of solid tumors. In addition, bone marrow-derived endothelial precursor cells may contribute to tumor angiogenesis. Recently angiogenesis induction was described in several hematologic neoplasms as leukemia, lymphoma, myelodysplastic syndrome and multiple myeloma (MM). Clinical angiogenesis research also termed as angiodiagnosis has established the prognostic relevance of markers of angiogenesis e.g., microvessel density and circulating levels of angiogenic peptides. Development of antiangiogenic treatment for hematologic neoplasms has recently been sparked by the success of Thalidomide (Thal) which has antiangiogenic properties in MM. Antiangiogenic treatment strategies are now being tested in clinical trials on several types of hematologic neoplasms.

引用

页码：695 / 705

页数：11

共 129 条

[1] Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes [J].

Aguayo, A ;

Kantarjian, H ;

Manshouri, T ;

Gidel, C ;

Estey, E ;

Thomas, D ;

Koller, C ;

Estrov, Z ;

O'Brien, S ;

Keating, M ;

Freireich, E ;

Albitar, M .

BLOOD, 2000, 96 (06) :2240-2245

[2] Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia [J].

Aguayo, A ;

Estey, E ;

Kantarjian, H ;

Mansouri, T ;

Gidel, C ;

Keating, M ;

Giles, F ;

Estrov, Z ;

Barlogie, B ;

Albitar, M .

BLOOD, 1999, 94 (11) :3717-3721

[3] Role of vascular endothelial growth factor/vascular permeability factor in the pathogenesis of Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphomas [J].

Aoki, Y ;

Tosato, G .

BLOOD, 1999, 94 (12) :4247-4254

[4] Bcl-2 expression correlates positively with serum basic fibroblast growth factor (bFGF) and negatively with cellular vascular endothelial growth factor (VEGF) in patients with chronic lymphocytic leukaemia [J].

Bairey, O ;

Zimra, Y ;

Shaklai, M ;

Rabizadeh, E .

BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (02) :400-406

[5] Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology [J].

Banks, RE ;

Forbes, MA ;

Kinsey, SE ;

Stanley, A ;

Ingham, E ;

Walters, C ;

Selby, PJ .

BRITISH JOURNAL OF CANCER, 1998, 77 (06) :956-964

[6] Soluble IL-6Rα upregulates IL-6, MMP-1 and MMP-2 secretion in bone marrow stromal cells [J].

Barillé, S ;

Collette, M ;

Thabard, W ;

Bleunven, C ;

Bataille, R ;

Amiot, M .

CYTOKINE, 2000, 12 (09) :1426-1429

[7]

Barillé S, 1999, J IMMUNOL, V163, P5723

[8] Metalloproteinases in multiple myeloma: Production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells [J].

Barille, S ;

Akhoundi, C ;

Collette, M ;

Mellerin, MP ;

Rapp, MJ ;

Harousseau, JL ;

Bataille, R ;

Amiot, M .

BLOOD, 1997, 90 (04) :1649-1655

[9] Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients [J].

Barlogie, B ;

Desikan, R ;

Eddlemon, P ;

Spencer, T ;

Zeldis, J ;

Munshi, N ;

Badros, A ;

Zangari, M ;

Anaissie, E ;

Epstein, J ;

Shaughnessy, J ;

Ayers, D ;

Spoon, D ;

Tricot, G .

BLOOD, 2001, 98 (02) :492-494

[10]

Bellamy WT, 1999, CANCER RES, V59, P728

← 1 2 3 4 5 6 7 8 9 10 →